Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

Background T-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical practice for hematological malignancies, the absence of sufficient infiltrating T cells is a major barrier for efficacy in solid tumors. In t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Rob C Hoeben, Sjoerd H van der Burg, Thorbald van Hall, Christianne Groeneveldt, Priscilla Kinderman, Diana J M van den Wollenberg, Ruben L van den Oever, Jim Middelburg, Dana A M Mustafa, Nadine van Montfoort
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2020-10-01
Edice:	Journal for ImmunoTherapy of Cancer
On-line přístup:	https://jitc.bmj.com/content/8/2/e001191.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!